Clinical Takeaway
People with PTSD and co-occurring substance use disorders who also use cannabis can still benefit meaningfully from trauma-focused treatments. Clinicians should not withhold or delay evidence-based PTSD care based on a patient’s cannabis use status.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis directly addresses a critical clinical gap by examining whether gold-standard trauma-focused treatments retain efficacy in the substantial subset of PTSD+SUD patients with concurrent cannabis use, whose outcomes have remained largely undocumented in the evidence base. The findings clarify treatment expectations and inform clinical decision-making for a high-prevalence comorbid population that practitioners frequently encounter but for whom efficacy data have been limited. Understanding differential treatment response in this group is essential for optimizing outcomes and potentially adjusting therapeutic protocols for patients with this complex symptom presentation.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 While this meta-analysis addresses a clinically important question about whether cannabis use compromises trauma-focused PTSD treatment outcomes in patients with co-occurring substance use disorders, several limitations warrant careful interpretation by practitioners. The analysis draws from only four of thirty-six available RCTs, which may not fully represent the heterogeneity of cannabis use patterns, potency, frequency, or route of administration that characterizes real-world patients, and the data pooling method itself could mask important subgroup effects. Additionally, the meta-analysis cannot establish causality or determine whether reduced treatment response relates to cannabis pharmacology, ongoing intoxication during therapy, underlying disease severity, or the behavioral patterns associated with heavy cannabis use. Clinically, these findings suggest that active cannabis use should prompt closer monitoring of PTSD treatment progress and consideration of concurrent substance use interventions, but should not automatically exclude patients from evidence-based trauma-focused therapies, which remain the standard of care for PTSD regardless of cannabis involvement.